Catherine Arnold

Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to read more

Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to its peers against 2006 and 2007 earnings and at a discount against our 2008 to 2010 forecast.

The U.S. case is more important because of the economic implications, ... a nice psychological boost but you can't extrapolate read more

The U.S. case is more important because of the economic implications, ... a nice psychological boost but you can't extrapolate the U.S. ruling from this because of the different legal standards.

We just can't get there. Maybe they see something we don't see.

We just can't get there. Maybe they see something we don't see.

After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings read more

After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings per share growth in 2007-2010.

We think the downside risk here is modest. Merck has fundamental challenges ahead based on its base business. We really read more

We think the downside risk here is modest. Merck has fundamental challenges ahead based on its base business. We really concluded the stock is trading incorporating these items.